Cargando…

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1

Patients with neurofibromatosis type 1 (NF1) have an increased lifetime risk for the development of nervous system tumors, including high-grade gliomas (glioblastoma). NF1 is associated with the loss of expression of neurofibromin 1 (NF1 gene product). This hyperactivates the mitogen-activated prote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awada, Gil, Serruys, Daphne, Schwarze, Julia Katharina, Van De Voorde, Lien, Duerinck, Johnny, Neyns, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548872/ https://www.ncbi.nlm.nih.gov/pubmed/33082744 http://dx.doi.org/10.1159/000509773

Ejemplares similares

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT)
por: Awada, Gil, et al.
Publicado: (2021)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

Overcoming the immune suppressive nature of glioblastoma by leveraging the surgical intervention - current status and future perspectives
por: Duerinck, Johnny, et al.
Publicado: (2023)

Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
por: Atkinson, Victoria G., et al.
Publicado: (2021)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
por: Draganova, Dafina, et al.
Publicado: (2015)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Dabrafenib- and trametinib-associated glomerular toxicity: A case report
por: Jo, Eunmi, et al.
Publicado: (2022)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Ocular side effects of Trametinib and Dabrafenib: a case report
por: Tarım, Bilge, et al.
Publicado: (2023)

Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement
por: Al Bayati, Ahmed, et al.
Publicado: (2018)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
por: Thawer, Alia, et al.
Publicado: (2021)

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
por: Williams, Casey B, et al.
Publicado: (2015)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report
por: Sundaram, Vinita Ruth, et al.
Publicado: (2018)

Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Molero-Senosiain, Mercedes, et al.
Publicado: (2022)

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
por: Bueno, Fernanda, et al.
Publicado: (2023)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
por: Su, Po-Lan, et al.
Publicado: (2021)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
por: Lima, Bárbara, et al.
Publicado: (2022)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Lee, Le Min, et al.
Publicado: (2014)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
por: Weart, Thomas C, et al.
Publicado: (2018)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Guillain-Barre Syndrome Secondary to the Use of Dabrafenib and Trametinib for the Treatment of Advanced Thyroid Carcinoma
por: Batra, Jaskaran, et al.
Publicado: (2023)

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
por: Noeparast, Amir, et al.
Publicado: (2016)

Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy
por: Kulkarni, Pruthali, et al.
Publicado: (2021)

Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
por: Duerinck, Johnny, et al.
Publicado: (2021)

Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature
por: Garrett, Giorgia L., et al.
Publicado: (2015)

Dabrafenib/tozinameran/trametinib: Lymph node enlargement and sarcoid-like reaction: 3 case reports
Publicado: (2021)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2021)

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients
por: Peng, Xue, et al.
Publicado: (2023)

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
por: Shin, Ji Eun, et al.
Publicado: (2022)

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma
por: Frazer, Ricky, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9luq8rm1u56m4oppeubjgsoaf2